Ascendis Pharma
$227.87Change from previous close: +0.25%Absolute change: +$0.56
At a glance
- Revenue growth
- +98.03%
- 2025 vs 2024
- Net margin
- -31.7%
- 2024: -104.0%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total assets | 2,286 | 2,003 | 1,303 | 1,155 | 1,088 | — |
| Current assets | 1,390 | 1,122 | 1,109 | 1,018 | 953 | — |
| Cash and equivalents | 812 | 573 | 616 | 539 | 494 | — |
| Receivables | 224 | 197 | 158 | 147 | 121 | — |
| Inventory | 311 | 314 | 302 | 302 | 303 | — |
| Net property, plant and equipment | 136 | 136 | 146 | 102 | 93.5 | — |
| Goodwill | — | — | 3.5 | — | — | — |
| Other intangible assets | — | — | 0.2 | — | — | — |
| Long-term investments | 30.5 | 23.6 | 32.5 | 28.3 | 34.9 | — |
| Current liabilities | 465 | 1,127 | 1,069 | 986 | 935 | — |
| Accounts payable | 104 | 78.6 | 90.7 | 78.6 | 93.7 | — |
| Long-term debt | 385 | 386 | 385 | 331 | 330 | — |
| Total debt | 450 | 897 | 872 | 814 | 793 | — |
| Total liabilities | 850 | 1,515 | 1,465 | 1,329 | 1,275 | — |
| Total equity (incl. minority) | 1,436 | 488 | -163 | -174 | -188 | — |
| Retained earnings | -1,878 | — | — | — | -2,666 | -2,658 |